Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

517
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
517
Tumor Progression02:07

Tumor Progression

6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
Cancer02:18

Cancer

49.2K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
49.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SPARSE ENCODING FOR MORE-INTERPRETABLE FEATURE-SELECTING REPRESENTATIONS IN PROBABILISTIC MATRIX FACTORIZATION.

... International Conference on Learning Representations·2026
Same author

Functional improvement is a better predictor of steady work than medical improvement for individuals with mental health conditions.

PLOS mental health·2026
Same author

Bayesian information theoretic model-averaging stochastic item selection for computer adaptive testing: compromise-free item exposure.

ArXiv·2025
Same author

Functional improvement is a better predictor of steady work than medical improvement for individuals with mental health conditions.

medRxiv : the preprint server for health sciences·2025
Same author

Evaluation of analgesic efficacy of transdermal patch versus oral diclofenac tablets in orthodontic patients undergoing multiple premolar extractions - A crossover study.

National journal of maxillofacial surgery·2025
Same author

Effectiveness of the Ticket to Work program in supporting employment among adults with disabilities.

medRxiv : the preprint server for health sciences·2025
Same journal

Smarter, Not More: The Rationale for Reducing Systematic Cores in the MRI-Targeted Biopsy Era.

The Canadian journal of urology·2026
Same journal

Ten Years of Progress in Advanced Prostate Cancer at the AUA.

The Canadian journal of urology·2026
Same journal

Electroacupuncture for sperm improvement in varicocele: a case report.

The Canadian journal of urology·2026
Same journal

Transperineal approach for penetrating injury of corpus spongiosum and bulbous urethra caused by vesicourethral foreign body: a case report.

The Canadian journal of urology·2026
Same journal

Penile fracture and concomitant severe urethral trauma-a case report and discussion of surgical approach.

The Canadian journal of urology·2026
Same journal

Management of retained bullet fragments from posterior urethra after gunshot wound: a case report.

The Canadian journal of urology·2026
See all related articles

Related Experiment Video

Updated: Aug 18, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.2K

Increasing aggressive prostate cancer.

Navin Shah1, Vladimir Ioffe2, Joshua C Chang3

  • 1Mid-Atlantic Urology Associates, Greenbelt, Maryland, USA.

The Canadian Journal of Urology
|December 10, 2022
PubMed
Summary
This summary is machine-generated.

Following 2012 guidelines, prostate biopsies decreased, but prostate cancer diagnoses, including high-grade cancers, increased. Annual screening for men aged 50-80, especially high-risk individuals, is recommended to reduce prostate cancer morbidity and mortality.

Keywords:
PSAUnited States Preventive Services Task Forceprostate cancerscreening

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.7K
Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

45.9K

Related Experiment Videos

Last Updated: Aug 18, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.2K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.7K
Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

45.9K

Area of Science:

  • Urology
  • Oncology
  • Public Health

Background:

  • The 2012 United States Preventive Services Task Force (USPSTF) released guidelines recommending against routine prostate cancer screening.
  • This study examines the impact of these guidelines on prostate biopsy (Pbx) characteristics and prostate cancer detection rates.

Purpose of the Study:

  • To compare prostate biopsy characteristics before and after the 2012 USPSTF prostate cancer screening guidelines.
  • To assess changes in prostate cancer incidence and grade following the implementation of the USPSTF recommendations.

Main Methods:

  • Retrospective comparative analysis of 2709 prostate biopsies from 2010-2012 (Group A) and 2018-2021 (Group B).
  • Data collected included patient demographics (age, race), prostate-specific antigen (PSA) levels, digital rectal examination (DRE) findings, and Gleason sum score (GSS).
  • Analysis focused on comparing biopsy rates, positive biopsy rates, and cancer characteristics between the two groups.

Main Results:

  • Annual prostate biopsies decreased from 567/year (Group A) to 335/year (Group B).
  • The annual positive biopsy rate increased from 134/year to 175/year.
  • High-grade prostate cancer (GSS 7-10) increased from 51.5% to 59%, and PSA levels ≥10 ng/mL increased from 25.4% to 31% in Group B compared to Group A.

Conclusions:

  • The 2012 USPSTF recommendations correlated with decreased prostate biopsies and increased detection of prostate cancer, including high-grade disease.
  • Results support annual prostate cancer screening for men aged 50-80, particularly high-risk groups like Black men and older individuals.
  • Annual PSA and DRE screening is likely to reduce prostate cancer morbidity, mortality, and healthcare costs.